Dexamethasone Induced Osteocyte Apoptosis in Steroid-Induced Femoral Head Osteonecrosis through ROS-Mediated Oxidative Stress

Abstract

Objective: Glucocorticoid (GC) overuse is strongly associated with steroid-induced osteonecrosis of the femoral head (SINFH). However, the underlying mechanism of SINFH remains unclear. This study aims to investigate the effect of dexamethasone (Dex)-induced oxidative stress on osteocyte apoptosis and the underlying mechanisms.

Methods: Ten patients with SINFH and 10 patients with developmental dysplasia of the hips (DDH) were enrolled in our study. Sixty rats were randomly assigned to the Control, Dex, Dex + N-Acetyl-L-cysteine (NAC), Dex + Dibenziodolium chloride (DPI), NAC, and DPI groups. Magnetic resonance imaging (MRI) was used to examine edema in the femoral head of rats. Histopathological staining was performed to assess osteonecrosis. Immunofluorescence staining with TUNEL and 8-OHdG was conducted to evaluate osteocyte apoptosis and oxidative damage. Immunohistochemical staining was carried out to detect the expression of NOX1, NOX2, and NOX4. Viability and apoptosis of MLO-Y4 cells were measured using the CCK-8 assay and TUNEL staining. 8-OHdG staining was conducted to detect oxidative stress. 2′,7′-Dichlorodihydrofluorescein diacetate (DCFH-DA) staining was performed to measure reactive oxygen species (ROS). The expression of NOX1, NOX2, and NOX4 in MLO-Y4 cells was analyzed by Western blotting. Multiple comparisons were performed using one-way analysis of variance (ANOVA).

Results: In patients and the rat model, hematoxylin–eosin (HE) staining revealed a significantly higher rate of empty lacunae in the SINFH group than in the DDH group. Immunofluorescence staining indicated a significant increase in TUNEL-positive cells and 8-OHdG-positive cells in the SINFH group compared to the DDH group. Immunohistochemical staining demonstrated a significant increase in the expression of NOX1, NOX2, and NOX4 proteins in SINFH patients compared to DDH patients. Moreover, immunohistochemical staining showed a significant increase in the proportion of NOX2-positive cells compared to the Control group in the femoral head of rats. In vitro, Dex significantly inhibited the viability of osteocyte cells and induced apoptosis. After Dex treatment, the intracellular ROS level increased. However, Dex treatment did not alter the expression of NOX proteins in vitro. Additionally, NAC and DPI inhibited the generation of intracellular ROS and partially alleviated osteocyte apoptosis in vivo and in vitro.

Conclusion: This study demonstrates that GC promotes apoptosis of osteocyte cells through ROS-induced oxidative stress. Furthermore, we found that the increased expression of NOXs induced by GC serves as an important source of ROS generation.

Keywords

apoptosis / osteocyte / oxidative stress / reactive oxygen species / steroid-induced femoral head osteonecrosis

References

[1] Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y. Oxidative stress in bone remodelling and disease. Trends Mol Med. 2009;15(10):468–477.

[2] Ghezzi P, Jaquet V, Marcucci F, Schmidt H. The oxidative stress theory of disease: levels of evidence and epistemological aspects. Brit J Pharmacol. 2017;174(12):1784–1796.

[3] Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell B. 2007;39(1):44–84.

[4] Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001;2(10):907–916.

[5] Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. J Bone Joint Surg. 2021;103(15):1451–1461.

[6] Li S, Kim MJ, Lee SH, Jin L, Cong W, Jeong HG, et al. Metallothionein 3 promotes osteoblast differentiation in C2C12 cells via reduction of oxidative stress. Int J Mol Sci. 2021;22(9):22.

[7] Wang N, Hao Y, Fu L. Trimethylamine-N-oxide promotes osteoclast differentiation and bone loss via activating ROS-dependent NF-kappaB signaling pathway. Nutrients. 2022;14(19):3955.

[8] Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol. 2003;38(6):605–614.

[9] Kong L, Wang B, Yang X, Guo H, Zhang K, Zhu Z, et al. Picrasidine I from Picrasma Quassioides suppresses osteoclastogenesis via inhibition of RANKL induced signaling pathways and attenuation of ROS production. Cell Physiol Biochem. 2017;43(4):1425–1435.

[10] Wang Y, Chen G. Regulation of oxidative stress-induced autophagy by ATG9A ubiquitination. Autophagy. 2022;18:2008–2010.

[11] Deng S, Zhou JL, Fang HS, Nie ZG, Chen S, Peng H. Sesamin protects the femoral head from osteonecrosis by inhibiting ROS-induced osteoblast apoptosis in rat model. Front Physiol. 2018;9:1787.

[12] Chen K, Liu Y, He J, Pavlos N, Wang C, Kenny J, et al. Steroid-induced osteonecrosis of the femoral head reveals enhanced reactive oxygen species and hyperactive osteoclasts. Int J Biol Sci. 2020;16(11):1888–1900.

[13] Guerado E, Caso E. The physiopathology of avascular necrosis of the femoral head: an update. Injury. 2016;47(Suppl 6):S16–S26.

[14] Glick EN. Necrosis of the femoral head in rheumatoid arthritis. Ann Rheum Dis. 1970;29(2):191.

[15] Guo B, Huang X, Cooper S, Broxmeyer HE. Glucocorticoid hormone-induced chromatin remodeling enhances human hematopoietic stem cell homing and engraftment. Nat med. 2017;23(4):424–428.

[16] Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrin MET. 2018;29(1):42–54.

[17] Cai J, Li H, Zhang C, Chen Z, Liu H, Lei F, et al. The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19. Cell Metab. 2021;33(2):258–269.

[18] Zhao DW, Yu M, Hu K, Wang W, Yang L, Wang B-J, et al. Prevalence of nontraumatic osteonecrosis of the femoral head and its associated risk factors in the Chinese population: results from a nationally representative survey. Chinese Med J-Peking. 2015;128(21):2843–2850.

[19] Yang N, Sun H, Xue Y, Zhang W, Wang H, Tao H, et al. Inhibition of MAGL activates the Keap1/Nrf2 pathway to attenuate glucocorticoid-induced osteonecrosis of the femoral head. Clin Transl Med. 2021;11(6):e447.

[20] Zhang F, Yan Y, Peng W, Wang L, Wang T, Xi Z, et al. PARK7 promotes repair in early steroid-induced osteonecrosis of the femoral head by enhancing resistance to stress-induced apoptosis in bone marrow mesenchymal stem cells via regulation of the Nrf2 signaling pathway. Cell Death Dis. 2021;12(10):940.

[21] Zhang S, Liu Y, Liang Q. Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS. Mol Med Rep. 2018;17(3):4307–4316.

[22] Wang T, Han C, Tian P, Li PF, Ma XL. Role of Teriparatide in glucocorticoid-induced osteoporosis through regulating cellular reactive oxygen species. Orthop Surg. 2018;10(2):152–159.

[23] Calder JD, Buttery L, Revell PA, Pearse M, Polak JM. Apoptosis–a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg Br. 2004;86(8):1209–1213.

[24] Jahn K, Lara-Castillo N, Brotto L, Mo CL, Johnson ML, Brotto M, et al. Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of beta-catenin. Eur Cells Mater. 2012;24:197–209.

[25] Robling AG, Bonewald LF. The osteocyte: new insights. Annu Rev Physiol. 2020;82:485–506.

[26] Bellido T. Osteocyte-driven bone remodeling. Calcified Tissue Int. 2014;94(1):25–34.

[27] Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocr Metab. 2000;85(8):2907–2912.

[28] Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41(2):183–190.

[29] Gao J, Cheng TS, Qin A, Pavlos NJ, Wang T, Song K, et al. Glucocorticoid impairs cell-cell communication by autophagy-mediated degradation of connexin 43 in osteocytes. Oncotarget. 2016;7(19):26966–26978.

[30] Brown DI, Griendling KK. Nox proteins in signal transduction. Free Radical Bio Med. 2009;47(9):1239–1253.

[31] Hoff P, Buttgereit F. NADPH oxidase 4 represents a potential target for the treatment of osteoporosis. Cell Mol Immunol. 2014;11(4):317–319.

[32] Schroder K. NADPH oxidases in bone homeostasis and osteoporosis. Free Radical Bio Med. 2019;132:67–72.

[33] Bai SC, Xu Q, Li H, Qin Y-F, Song L-C, Wang C-G, et al. NADPH oxidase isoforms are involved in glucocorticoid-induced preosteoblast apoptosis. Oxid Med Cell Longev. 2019;2019:9192413.

[34] Wang Z, Guo J. Mechanical induction of BMP-7 in osteocyte blocks glucocorticoid-induced apoptosis through PI3K/AKT/GSK3beta pathway. Cell Biochem Biophys. 2013;67(2):567–574.

[35] Yin J, Han L, Cong W. Alpinumisoflavone rescues glucocorticoid-induced apoptosis of osteocytes via suppressing Nox2-dependent ROS generation. Pharmacol Rep. 2018;70(2):270–276.

[36] Takeno A, Kanazawa I, Tanaka K, Notsu M, Yokomoto-Umakoshi M, Sugimoto T. Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2. Endocr J. 2016;63(4):389–395.

[37] Zheng LZ, Wang JL, Kong L, Huang L, Tian L, Pang QQ, et al. Steroid-associated osteonecrosis animal model in rats. J Orthop Transl. 2018;13:13–24.

[38] Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell … and more. Endocr rev. 2013;34(5):658–690.

[39] Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42(4):606–615.

[40] Feng R, Feng L, Yuan Z, Wang D, Wang F, Tan B, et al. Icariin protects against glucocorticoid-induced osteoporosis in vitro and prevents glucocorticoid-induced osteocyte apoptosis in vivo. Cell Biochem Biophys. 2013;67(1):189–197.

[41] Chen JR, Lazarenko OP, Shankar K, Blackburn ML, Lumpkin CK, Badger TM, et al. Inhibition of NADPH oxidases prevents chronic ethanol-induced bone loss in female rats. J Pharmacol Exp Ther. 2011;336(3):734–742.

[42] Lyons JS, Joca HC, Law RA, Williams KM, Kerr JP, Shi G, et al. Microtubules tune mechanotransduction through NOX2 and TRPV4 to decrease sclerostin abundance in osteocytes. Sci Signal. 2017;10(506):10.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.